Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

GAITHERSBURG, Md. , Oct. 19, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to provide a first booster dose at least six months after completion of primary vaccination with an authorized or approved COVID-19 vaccine to individuals 18 years of age and older for whom an FDA-authorized mRNA bivalent COVID-19 booster vaccine is not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Novavax COVID-19 Vaccine, Adjuvanted because they would otherwise not receive a booster dose of a COVID-19 vaccine.

U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults

Novavax's Covid shots rely on protein technology used in other vaccines for decades, rather than the messenger RNA used in the Pfizer and Moderna vaccines.

FDA authorizes Novavax's Covid shots as mix-and-match booster to Pfizer or Moderna

Teladoc

Both stocks soared during the early days of the pandemic.

More Likely to Double First: Teladoc or Novavax?

Etsy

NextEra Energy

You don't need a boatload of cash to begin building wealth on Wall Street.

Got $300? 3 Genius Stocks to Buy on the Dip

GoodRx Holdings

Matterport

Upstart Holdings

These four tech stocks are down nearly 90%.

Should You Buy the Nasdaq's 4 Worst-Performing Stocks of 2022?

Investors ding the biotech's shares one day after it reported quite good news about an experimental vaccine.

Why Novavax Stock Had an Ugly Friday

Novavax (NVAX) reports positive data from its phase I/II study evaluating a combination of its COVID-19 and the seasonal influenza vaccine.

Novavax (NVAX) Reports Positive Data on COVID/FLU Combo Jab Study

The vaccine maker had a flurry of good news.

Why Novavax Stock Is Skyrocketing This Week

Shares of Novavax Inc. NVAX, +6.69% were down 3.4% in premarket trading on Thursday after the company said its combination COVID-19 vaccine and flu shot candidate generated an immune response in a Phase 1/2 clinical trial. Novavax also said that the safety and tolerability of the combination vaccine was consistent with getting a standalone COVID-19 vaccine or flu shot, and it plans to begin a confirmatory Phase 2 clinical trial this year.

Novavax says its combination COVID-19 and flu vaccine produced an immune response

Trial is the first of its kind to evaluate a combined COVID-19 and influenza vaccine Dose insights from Phase 1/2 trial will inform Phase 2 confirmation trial to begin in late 2022 GAITHERSBURG, Md. , Oct. 13, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced positive results from the Phase 1/2 clinical trial of its COVID-19-Influenza Combination (CIC) vaccine candidate.

Novavax COVID-19-Influenza Combination Vaccine Candidate Induced Antibody and T-Cell Responses Against SARS-CoV-2 and Homologous and Heterologous Influenza Strains

Large holdings of stocks by institutional investors signal potential big price moves. That's because large investors can infuse the necessary liquidity to fuel huge market volatility.

Institutional investors are betting on Novavax. How attractive is the stock?

Source: cortex-film / Shutterstock.com Novavax (NASDAQ: NVAX ) stock is on the move Wednesday following positive data from its Phase 3 PREVENT-19 trial and Study 307. Both of these cover the use of the company's Covid-19 vaccine in development.

Why Is Novavax (NVAX) Stock in the Spotlight Today?

Shares of Novavax Inc. NVAX, +6.69% jumped 1.7% in premarket trading on Wednesday after the company said its COVID-19 vaccine boosted antibody levels when used as a booster. The data, from a Phase 3 clinical trial, tested a third shot in adults who had been vaccinated with Novavax's initial series of shots 8 or 11 months prior.

Novavax has fresh data showing that its COVID-19 shot works as a booster

Novavax Inc said on Wednesday data from studies in adults and adolescents showed that the booster dose of its COVID vaccine produced robust antibodies against several Omicron variants, including BA.1, BA.2 and BA.5.

Novavax says COVID booster dose shows benefit against Omicron variants

Homologous boosting with the prototype Novavax COVID-19 vaccine induced robust antibody titers for Omicron BA.1, BA.2, and BA.5 Study 307 (Lot Consistency) achieved its primary endpoint, showing that three vaccine lots induced a comparable immune response thereby demonstrating the consistency of the manufacturing process A durable immunogenicity response was observed following primary vaccination as well as boosting which matched the levels previously associated with protection GAITHERSBURG, Md. , Oct. 12, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today presented data from the Phase 3 PREVENT-19 trial and Study 307 (Lot Consistency) at the World Vaccine Congress Europe 2022.

Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants

Source: Ascannio/Shutterstock.com Novavax (NASDAQ: NVAX ) stock closed higher by 6.7% today. Currently, the company is slated to share positive data from Phase 1 and 2 trials concerning its Covid-19-Influenza Combination (CIC) vaccine at the World Vaccine Congress (WVC) Europe 2022 event on Oct. 13.

5 Investors Betting Big on Novavax (NVAX) Stock

Source: vovidzha / Shutterstock.com Today's incredible price action with vaccine maker Novavax (NASDAQ: NVAX ) has started to gain significant attention. At one point today, NVAX stock surged more than 23% to intraday highs.

Novavax (NVAX) Stock Pops 8% With Vaccine Talks Underway

The Federal Office of Public Health in Switzerland recommends Novavax's (NVAX) COVID-19 vaccine, Nuvaxovid, as a booster for both heterologous and homologous use in adults aged 18 years and older.

Novavax's (NVAX) COVID-19 Booster Recommended in Switzerland

Shares of Novavax (NASDAQ: NVAX ) are in focus, as the biotechnology company will share data from its Covid-19-Influenza Combination (CIC) vaccine candidate for Phase 1 and 2 trials at the World Vaccine Congress (WVC) Europe 2022 event tomorrow. Novavax will also share data on its Covid-19 vaccine as a homologous and heterologous booster for adults over 18 and adolescents between 12 and 17.

Dear NVAX Stock Fans, Mark Your Calendars for Oct. 11

The company reported positive developments in Switzerland and South Korea.

Why Novavax Stock Is Jumping Today

New safety and immunogenicity data for the COVID-19-Influenza Combination vaccine candidate Phase 1/2 trial will be presented New data will be presented for Novavax' COVID-19 vaccine supporting its use as a homologous and heterologous booster in adults aged 18 and older and adolescents aged 12 through 17 Updated Phase 3 PREVENT-19 data and new Study 307: Lot Consistency data will reinforce COVID-19 vaccine's benefits as an adult heterologous booster GAITHERSBURG, Md. , Oct. 10, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, will present new safety and immunogenicity data from the first Phase 1/2 COVID-Influenza Combination (CIC) dose-finding trial evaluating its CIC vaccine candidate at the World Vaccine Congress (WVC) Europe, October 11 to 14, 2022.

Novavax to Share New Data from Growing Vaccine Portfolio at World Vaccine Congress Europe 2022

Is Novavax stock a sell after its second-quarter disappointment led to a guidance cut? NVAX stock ranks low among biotechs.

Novavax Is No Longer Expected To Become Profitable This Year — Is It A Sell?

Despite being the first protein-based COVID-19 vaccine in many markets, Novavax's (NVAX) delayed product launch severely affected the company's prospects.

Why Novavax's (NVAX) COVID Vaccine Struggles for Market Share?

AbbVie

Abbott Labs

Acadia Healthcare

AstraZeneca

Bristol-Myers

Cardinal Health

Cigna

CVS Health

Johnson & Johnson

Merck

Novartis

Pfizer

Regeneron Pharmaceuticals

UnitedHealth Group

Health care stocks are traditionally a defensive play for investors in a falling market. It's a rich market with blue chip insurance providers, service providers, pharmaceutical companies, retailers, and tech players.

Health Care Stocks: Reviewing The Best Of The Industry

Novavax is the hypercoaster of stocks having crested $300 in 02/2022, falling to

News for Novavax Stock (NVAX)